Ultra-Deep Sequencing of HIV-1 Reverse Transcriptase Before Start of an NNRTI-based Regimen in Treatment-naive Patients (Q58415442)

1

0 references

Chris Verhofstede

2

0 references

Ina Vandenbroucke

3

0 references

Sylvie Dinakis

4

0 references

Veerle Van Eygen

5

0 references

Kim Thys

6

0 references

Bart Winters

7

0 references

Jeroen Aerssens

8

0 references

Dirk Vogelaers

9

0 references

Lieven J. Stuyver

Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure

10

0 references

language of work or name

English

0 references

publication date

April 2012

0 references

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

Virology

0 references

volume

426

0 references

issue

1

0 references

page(s)

7-11

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Detection of minor drug-resistant populations by parallel allele-specific sequencing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Transmission of HIV‐1 Drug‐Resistant Variants: Prevalence and Effect on Treatment Outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Analysis of Low-Frequency Mutations Associated with Drug Resistance to Raltegravir before Antiretroviral Treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Detection of minor populations of drug-resistant HIV-1 in acute seroconverters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Minor Variant Detection in Amplicons using 454 Massive Parallel Pyrosequencing: Experiences and Considerations for Successful Applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Evolution of drug-resistant viral populations during interruption of antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.002